Sensitive and Specific Preclinical Identification of Alzheimer Disease: A Key to Novel Intervention Development.
Sensitive and Specific Preclinical Identification of Alzheimer Disease: A Key to Novel Intervention Development.
复制标题
阿尔茨海默病的灵敏和特异性临床前鉴定：新型干预开发的关键。
DOI：
10.1016/j.jagp.2016.07.010
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Palmer,BartonW
中科院分区：
文献类型：
--
作者：
Palmer,BartonW
Early detection of preclinical Alzheimer’s disease is clearly critical to development of effective interventions. By the time the clinical symptoms manifest, much of the neuropathological damage is already present. Hope for truly effective treatments rests in being able to intervene early in the pathological process, before the cascade of damage is well-underway (Cummings, Doody, & Clark, 2007).Over the past two decades, researchers have found substantial evidence pointing to episodic memory tests as a sensitive measure to identify those in the very earliest stages of Alzheimer’s disease (Bondi et al., 2008). Of note, contemporary episodic memory tests are essentially modified forms of some of the most enduring measures in existence. For example, the Rey Auditory Verbal Learning Test (RAVLT), a list learning task which remains widely used and is also the precursor to the popular California Verbal Learning Test (CLVT) was initially introduced in the early 1900s by Édouard Claparède (Boake, 2000). But there remains a need to identify high-risk people even earlier in the process of pathological change. For example, data from the well-publicized “Nun study” indicated that an index of “idea density”(number of ideas expressed per 10 words) in autobiographies written at age 18–32 predicted subsequent risk of development of cognitive impairment or dementia approximately six decades later (Riley, Snowdon, Desrosiers, & Markesbery, 2005). Such findings raise the possibility that there are subtle forms of subclinical neuropathology present decades before the emergence of mild cognitive impairment or dementia.
